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Abstract
The study aimed to identify targets for quality improvement in antifungal use in European hospitals and determine the variability of such
prescribing. Hospitals that participated in the European Surveillance of Antimicrobial Consumption Point Prevalence Surveys (ESAC-
PPS) were included. The WHO Anatomical Therapeutic Chemical (ATC) classiﬁcation for ‘antimycotics for systemic use’ (J02) 2009 ver-
sion was used. Demographic data and information about indications and diagnoses were collected in 2008 and 2009. From 99 053
patients, 29 324 (29.6%) received antimicrobials. Antifungals represented 1529 of 40 878 (3.7%) antimicrobials. Antifungals were mainly
(54.2%) administered orally. Hospital-acquired infections represented 44.5% of indications for antifungals followed by medical prophy-
laxis at 31.2%. The site of infection was not deﬁned in 36.0% of cases but the most commonly targeted sites were respiratory (19.2%)
and gastrointestinal (18.8%). The most used antifungal was ﬂuconazole (60.5%) followed by caspofungin (10.5%). Antifungal–antibacterial
combinations were frequently used (77.5%). The predominance of ﬂuconazole use in participating hospitals could result in an increase in
prevalence of inherently resistant fungi, increasing the need for newer antifungals. Although acknowledging that antifungal prophylaxis in
the immunocompromised host needs further exploration, repetitive surveys using ESAC-PPS methodology may help to monitor the
effects of interventions set to regulate antifungal use.
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Introduction
The use of antifungal drugs, including newer agents, has
increased in the last two decades, escalating concern about
the development of resistance [1]. Most published data
report on speciﬁc departments such as haematology–oncol-
ogy and intensive-care units [2–4]. Publications reporting on
whole hospital use of systemic antifungals are limited [1,5,6].
Furthermore, these reports were limited to either a single
institution or a few hospitals from the same country. In addi-
tion, no point-prevalence-survey speciﬁcally dedicated to
antifungal use could be identiﬁed on PubMed. In point-preva-
lence-surveys on antimicrobial consumption the proportion
of antifungals ranged from 3.8% (eight antimycotics for sys-
temic use out of 211 antimicrobials) plus another eight
(3.8%) ‘antifungals for dermatological use’ giving a total of
7.6% in a paediatric hospital in north-western Russia [7] to
6.7% (88 of 1317 antimicrobials) in Turkish paediatric hospi-
tals [8]. This shows that different inclusion and exclusion
criteria can give rise to different values being reported.
The epidemiology of invasive fungal infections varies by
geographic region, age and time [9]. The improvement in
quality of health care has increased the population at risk for
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developing invasive fungal infections. The most common
yeast infections are caused by Candida spp. and Cryptococcus
spp. whereas Aspergillus spp. remain the most frequently iso-
lated moulds, although other ﬁlamentous fungi (Fusarium
spp., Scedosporium spp., Penicillium spp. and Zygomycetes) are
becoming more common [10–12]. For example, Candida albi-
cans is the major pathogen in candidaemia, found in between
50% of candidaemia in Spain to 70% in Finland and Norway
[9,13,14]. In a Spanish hospital the proportion of non-albi-
cans candidaemia was greater than that caused by C. albicans
[15]. The ARTEMIS DISK global antifungal susceptibility sur-
veillance programme for 1997–2007 and other smaller stud-
ies have reported an increase in the proportion of Candida
glabrata, a less susceptible species than C. albicans [16,17].
Despite non-albicans candidaemia being more likely to be
ﬂuconazole resistant, the crude and 14-day mortality rates
from a Brazilian intensive-care unit were comparable [18].
Furthermore, the incidence of candidaemia caused both by
C. albicans and non-albicans Candida spp. was reported to
have increased in a report from Austria [6]. Therefore,
rational use of antifungal agents is an important aspect of any
antimicrobial stewardship programme. Antifungals are pre-
scribed as an empiric or targeted therapeutic indication, as
pre-emptive treatment, or as long-term medical prophylaxis
in immunocompromised patients (e.g. in neutropenic patients
[19], liver transplant patients [20] or haematopoietic stem
cell transplantation [21,22]). Shifting from empirical to pre-
emptive therapy may reduce the number of patients treated
unnecessarily [23]. A recent systematic review suggested that
some drugs may be superior to others depending on the
speciﬁc indications (empiric vs. pre-emptive vs. directed ther-
apy) [24]. Therefore, validation of pre-emptive strategies will
probably lead to the development of evidence-based guide-
lines for targeted use of antifungals [25].
The ﬁrst step in rationalizing prescription is the surveil-
lance of use with the aim of identifying areas of practice that
could be improved. In fact, the objectives of this report were
to determine the variability or predictability of antifungal use
in participating hospitals, and to identify targets for quality
improvement for antifungal use in hospitalized patients.
Patients and Methods
The methodology used was the standardized European Sur-
veillance of Antimicrobial Consumption Point Prevalence Sur-
veys (ESAC-PPS) methodology [26]. In brief, this
methodology required participating hospitals to carry out the
survey, in a maximum of 2 weeks, within a given time win-
dow (May–June 2008 for the ﬁrst survey and May–June 2009
for the second survey). Each department (e.g. Medical) had
to be completed in a single day. All inpatients, i.e. patients
whose total hospital stay was at least 24 h, on the respective
ward census at 08:00 h on the survey date had to be
assessed and included in the denominator. This information
was recorded on the ‘department form’.
Patients receiving antimicrobials at 08:00 h on the day of
the survey were identiﬁed and the details of prophylaxis
or therapy were recorded using the ‘patient-form’. Antimi-
crobials in J01, J02, A07AA, P01AB, D01BA, and J04AB02
according to the World Health Organization (WHO) Col-
laborating Centre for Drug Statistics anatomical therapeutic
chemical (ATC) classiﬁcation were included in the survey.
Rifampicin was recorded for any indication excluding tuber-
culosis. Those patients on systemic antifungal agents (J02)
were extracted from the respective databases of ESAC-PPS
of 2008 and 2009 for the purpose of this analysis. These
were merged into one database for systemic antifungals.
All antimicrobial treatment for the same indication in these
same patients was taken into consideration for analysis of
combination therapy of antifungal with antibacterial
agent(s).
Hospitals that participated in both PPS were considered
only once taking into account the most recent year of partic-
ipation (2009). Fifty hospitals (from 28 European countries)
participated in ESAC-PPS 2008, 36 of which formed part of
the 172 (from 23 countries) hospitals that participated in
ESAC-PPS 2009 so the total number of hospitals was 186.
For those hospitals that participated in both surveys a com-
parison of antifungal prevalence was performed.
Statistical analysis
To determine the validity of differences between propor-
tions, the exact binomial 95% conﬁdence interval was calcu-
lated. Whenever the upper limit of the lower proportion did
not overlap with the lower limit of the higher proportion
the difference was unlikely to be due to chance. The Z-test
was used to compare proportions of antibacterial versus
antifungal use in different age groups.
Results
Hospitals
Out of 186 hospitals, 39 (21.5%) did not record any use of
antifungal agents on the survey date. For the remaining 147
hospitals the median proportion of antifungals was 2.5% (in-
terquartile range 0.8–4.6%) of all anti-infective agents. The 28
hospitals that participated in both surveys and recorded use
of antifungals showed only marginal differences between the
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two surveys. Indeed a lower total number of antifungal pre-
scriptions with a higher median was observed in 2008 (2008:
258 prescriptions—median 6.5, interquartile range 2.0–11.3;
2009: 317 prescriptions—median 6.0, interquartile range
2.0–11.0).
Patients
From a total of 99 053 admitted patients, 29 324 (29.6%)
received antimicrobials. Antifungals represented 3.7% (1529
prescriptions in 1499 patients) of all 40 878 antimicrobial
prescriptions (Fig. 1). Hence, 5.1% (1499 of 29 324) of all
treated patients received antifungals. The number and pro-
portion of antifungal prescriptions increased up to the
60–75-year age group (31.2% of total antifungal prescrip-
tions) and decreased in patients >75 years, unlike antibacteri-
als, the proportion of which kept on increasing with age
(Fig. 2). (The data shown in this ﬁgure were presented dur-
ing an oral presentation during the 20th European Congress
of Clinical Microbiology and Infectious Diseases: Vienna, Aus-
tria on 13 April 2010 without the p values). The proportions
were signiﬁcantly different in all age groups except the youn-
ger two groups.
99 053 included patients
1499 (5.1%) treated patients with
1529 (3.7%) prescriptions 
Patients with antifungal therapy:
Combination with antibacterial 
agents?
No: 344 patients (22.5%) Yes: 1185 patients (77.5%)
Mainly fluconazole plus: Frequency
Penicillin/enzyme inhibitor
71 (4.8%)Fluoroquinolone
43 (2.9%)Co-trimoxazole
Fluconazole 925 (60.5%)
160 (10.5%)
140 (9.2%)
115 (7.5%)
106 (6.9%)
83 (5.4%)
Caspofungin
Amphotericin B
Voriconazole
Itraconazole
Other antifungals
Mainly fluconazole
(266  patients) 
29 324 treated patients (29.6%)
(40 878 prescriptions)
Patients with antimicrobial therapy:
(%)
47 (3.1%)Carbapenem
76 (5.1%)
FIG. 1. Flowchart depicting a summary of: included patients; antifungal drugs used and combination of antibacterials with ﬂuconazole.
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Prescriptions
The proportion of oral prescriptions was 54.2% (95% CI
51.6–56.7%) for all antifungal agents and 61.2% (95% CI
58.1–64.5%) for ﬂuconazole. The latter was the most used
antifungal agent accounting for 60.5% (95% CI 58.0–63.0%) of
prescriptions (Fig. 1). Caspofungin, a relatively novel echino-
candin, was the second most used antifungal agent (10.5%;
95% CI 9.0–12.1%). The relative proportion for the ﬁve most
commonly prescribed antifungal agents is shown in Fig. 3.
Antifungals were mainly used in combination with antibacte-
rial agents (77.1%; 95%CI 74.9–79.2%) and not as monotherapy.
The most frequently used combinations included ﬂuconazole
plus either, a b-lactam (penicillin with enzyme inhibitor or carb-
apenem—50.5%; 95% CI 47.9–53.1%) or, a ﬂuoroquinolone
(ciproﬂoxacin or levoﬂoxacin—16.3%; 95%CI 14.4–18.2%).
Hospital-acquired infections represented 44.5% (95% CI
42.0–47.1%) of indications for antifungals followed by medical
prophylaxis at 31.2% (95% CI 28.9–33.6%). The overall propor-
tion of antifungal use for HAI ranged from 1.2% in patients
admitted in surgical departments to 5.8% in patients admitted
in intensive-care units. The proportion of antifungal agents also
varied by indication. These proportions ranged from 15.9% of
antimicrobial agents used in medical prophylaxis to 0.2% of
drugs used for surgical prophylaxis. The most commonly tar-
geted sites were respiratory (19.2%) and gastrointestinal
(18.8%). However, in 36.0% of cases no speciﬁc site was tar-
geted. This was mainly attributed to 51.4% of medical prophy-
laxis and 33.9% of HAI. Figure 4 highlights differences in the
actual antifungal agents by specialty and indication, respectively.
For example, caspofungin was more frequently used in inten-
sive-care units and for HAIs whereas itraconazole was mainly
used as medical prophylaxis within medical departments.
Specialty and indication also inﬂuenced considerably the dis-
tribution of route of administration. The parenteral route was
dominant in intensive-care units (88.3%; 95% CI 81.9–91.9%
parenteral vs. 11.7%; 95% CI 8.1–16.1% oral) whereas the oral
route was predominant in medical wards (66.3%; 95% CI 63.3–
69.1% oral vs. 33.7%; 95% CI 30.9–26.7% parenteral). In surgi-
cal patients the predominance of the parenteral route (55.4%;
95% CI 47.5–53.0%) was not signiﬁcantly different from the
oral route (44.6%; 95% CI 37.0–52.5%). With respect to route
of administration by indication, the treatment of community-
acquired infections showed the least difference with 43.5%
(95% CI 36.2–48.9%) parenteral and 56.5% (95% CI 51.1–
61.8%) oral. In medical prophylaxis the oral route was used
predominantly (76.5%; 95% CI 72.5–80.3%). Conversely, in the
treatment of HAI the most used route of administration was
the parenteral route (62.8%; 95% CI 59.1–66.5%).
Discussion
Antifungal agents represent a relatively small proportion of
antimicrobial agents within the hospital setting. In our study
p = 0.0137* p < 0.0001*
p < 0.0001*
p = 0.0001*
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FIG. 2. Proportion of antimicrobial prescriptions (antifungals (dark red) and antibacterials (blue)) by different age group. The p-value is shown
above each age group column pair and denote by an * whenever signiﬁcant.
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the proportion of antifungal agents was equivalent to a med-
ian of 2.5% or an overall proportion of 3.7%. However, cer-
tain departments (e.g. intensive-care and oncology–
haematology units) are more intense users [1]. In our study
medical prophylaxis accounted for >30% of antifungal use
and could therefore be used as a quality indicator by speciﬁc
institutions or health systems. The epidemiology of opportu-
nistic invasive fungal pathogens varies by type of patient [27]
so different departments would have speciﬁc consumption
patterns. Therefore, prophylaxis in the immunocompromised
host needs further exploration and should be studied in the
speciﬁc context of this sub-population.
The use of empiric ﬂuconazole in intensive-care units in
adults with risk factors for invasive candidiasis is widely prac-
tised despite the fact that it is not clearly proven to improve
outcome compared with placebo [28]. Furthermore, if used
at all, it should be reserved for patients with a high risk of
developing fungal infections [29] or in units with high inci-
dence of candidaemia [30].
In our study the second most used antifungal for medical
prophylaxis was itraconazole. Medical prophylaxis is widely
practised in immunocompromised patients who are undergo-
ing chemotherapy or radiotherapy or who are receiving
immunosuppressant therapy following a transplant. Haema-
tology–oncology units have already been identiﬁed as intense
users of systemic antifungal agents in the early 2000s [1].
Case reports from Singapore reported that antifungal pro-
phylaxis with newer agents (caspofungin and voriconazole)
resulted in patients developing resistant invasive fungal infec-
tions [31]. This suggests that previous exposure to antifungal
agents is a risk factor for resistant fungal infections. There-
fore prophylaxis should not be used in all patients. Indeed in
liver transplant patients without high-risk factors, antifungal
prophylaxis does not seem to be justiﬁed [20] whereas, in
haematopoietic stem cell transplantation the newer agent
micafungin was reported to be more cost-effective than
ﬂuconazole [21,22].
Medical prophylaxis is also encountered in the commu-
nity setting as most patients receiving antifungal prophylaxis
during their immunosuppression are admitted as day-cases
for administration of their chemotherapy. However, this use
in the community is minimal. In fact, antifungal consumption
in the community relies on terbinaﬁne (>50% of prescrip-
tions) [32]. Our results showed a predominance of a differ-
ent drug (ﬂuconazole >50%), whereas terbinaﬁne was only
used in nine of our patients so it was not included in this
analysis.
This high predominance of ﬂuconazole use is another
potential quality indicator. Its use has been reported to
remain unchanged with the introduction of new antifungal
classes [1]. Indeed, following the introduction of the ﬁrst
novel antifungal agent, voriconazole, in 2003, the latter was
being used instead of amphotericin B rather than ﬂuconazole.
Our results, which are similar to those from an intensive-
care units study from the USA, [33] showed that caspofungin
was the second most used antifungal agent but voriconazole
ranked lower than amphotericin B. This predominance of
ﬂuconazole could lead to a rise in the prevalence of inher-
ently resistant fungi (e.g. Candida krusei and Candida glabrata)
[34]. Fluconazole prophylaxis in a French hospital decreased
the cases of candidaemia but increased the prevalence of
C. glabrata isolation [5]. Over-reliance on ﬂuconazole could
also promote the development of resistance in Candida spp.
that are usually considered to be ﬂuconazole susceptible (e.g.
C. albicans). However, increased consumption of newer anti-
fungals also has its untoward effects. Increased caspofungin
usage was associated with an increased incidence of Candida
parapsilosis candidaemia, as well as, a reduction in Candida
tropicalis and C. glabrata candidaemia [35]. Certain laborato-
ries only carry out species identiﬁcation for Candida spp. as
standard practice because this is usually synonymous with a
speciﬁc susceptibility proﬁle. Antifungal susceptibility testing
might become a necessary standard practice in clinical prac-
tice for Candida spp.
IndicationSpecialty
Fluconazole Caspofungin Amphotericin B Voriconazole Itraconazole Posaconazole Other AF
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FIG. 4. Varying proportion of antifungals by specialty and by indication.
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Unnecessary or inappropriate antifungal use is another
indicator of quality because, apart from selecting for resis-
tance, it contributes to elevated pharmacy costs [36]. In vari-
ous settings, such as the intensive-care setting, more costly
second-line antifungal agents are often started based on iso-
lation of Candida spp. from respiratory secretions, which
should be regarded as contaminants [1]. Indeed inappropriate
antifungal therapy has been reported as being ‘frequent’ and
associated with increased length of stay in intensive-care
units [33].
Another possible performance indicator is the route of
administration. This has to be based on speciﬁc departments
because there is no universal standard quantifying what the
appropriate percentage of oral antifungal use might be in dif-
ferent settings. For instance, a high proportion of parenteral
ﬂuconazole in haematology–oncology patients could be inap-
propriate because this drug has 90% oral bioavailability [37].
In addition, haematology–oncology patients would be prone
to opportunistic fungal infections including moulds (e.g. Asper-
gillus spp.) [38]. Therefore, ﬂuconazole would not be the
best drug because it is not active against these opportunistic
pathogens.
A possible improvement on our methodology could be
the inclusion of speciﬁc fungal infection identiﬁcation to
enable comment on the drugs used in the treatment of such
infection. This was, however, not possible in our study
because we did not collect such detailed information on the
infections. However, the spin-off PPS organized by the Euro-
pean Centre for Disease Prevention and Control will collect
data on HAI, microorganisms as well as antimicrobials used
[39]. This could possibly analyse data for correlation
between fungal infections and antifungal use.
The lower proportion of antifungals prescribed in patients
aged 75 years or more compared with that of antibacterial
agents was not anticipated. These patients have a lower level
of immunity and are more likely to acquire not only bacterial
but also fungal infections. Therefore, it would have been
expected that the respective prescription distribution for
both antibacterial and antifungal agents would follow similar
trends.
In conclusion, continual surveillance of antifungal consump-
tion using the ESAC-PPS methodology is feasible and could
identify lacunae in guidance or practice. In turn, targeted
interventions to encourage appropriate antifungal prescribing
could be put in place. The effectiveness of such interventions
in improving the quality of antifungal prescriptions could be
evaluated by means of repeated surveys. This is important
both from the epidemiological aspect of slowing down devel-
opment of resistance as well as reducing costs because novel
antifungal agents account for a considerable proportion of
pharmacy costs.
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